

Original article:

EFFECT OF SUBCLINICAL, CLINICAL AND SUPRACLINICAL DOSES OF CALCIUM CHANNEL BLOCKERS ON MODELS OF DRUG-INDUCED HEPATOTOXICITY IN RATS

Iniviefien B. Okwa¹, Abidemi J. Akindele^{1*}, Esther O. Agbaje¹, Oladoyin T. Oshinuga¹, Chidozie C. Anunobi², Olufunmilayo O. Adeyemi¹

¹ Department of Pharmacology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, P.M.B. 12003, Lagos, Nigeria

² Department of Morbid Anatomy, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, P.M.B. 12003, Lagos, Nigeria

* corresponding author: Abidemi J. Akindele (Ph.D), Department of Pharmacology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, P.M.B. 12003 Lagos, Nigeria; Tel: +2348062359726; E-mail: ajakindele@cmul.edu.ng, jakindele@unilag.edu.ng

ABSTRACT

Drug-related hepatotoxicity is the leading cause of acute liver failure, and hepatic problems are responsible for a significant number of liver transplantations and deaths worldwide. Calcium has been associated with various metabolic processes that lead to cell death and apoptosis, and increased cytosolic Ca²⁺ has been implicated in hepatotoxicity. This study was designed to investigate the effects of calcium channel blockers (CCBs) on isoniazid-rifampicin, zidovudine and erythromycin-induced hepatotoxicity in rats. Treatment groups comprised control, hepatotoxicant, hepatotoxicant along with each of silymarin, nifedipine, verapamil and diltiazem at subclinical, clinical and supraclinical doses. A day to the end of treatment for each model, rats were subjected to the hexobarbitone-induced hypnosis test. On the last days of treatment, blood samples were collected and serum was analyzed for relevant biochemical parameters. Animals were sacrificed after blood collection and livers were harvested, and samples obtained for *in vivo* antioxidant indices assay and histopathology. The hepatotoxicants significantly increased serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), as well as duration of sleep in the hypnosis test. These drugs significantly reduced the hepatic levels of reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and increased the level of malondialdehyde (MDA). The CCBs at the various doses significantly reversed the effects of isoniazid-rifampicin, zidovudine and erythromycin. The results obtained in this study suggest that the CCBs possess hepatoprotective activity in drug-induced hepatotoxicity and may be beneficial at the subclinical and clinical doses.

Keywords: Calcium channel blockers, drug-induced hepatotoxicity, isoniazid, rifampicin, zidovudine, erythromycin

INTRODUCTION

The liver is a vital organ involved in detoxification, protein synthesis and pro-

duction of biochemicals essential for the process of digestion (e.g. bile). It plays a major role in metabolism, glycogen storage, decomposition of red blood cells,

plasma protein synthesis, hormone production and detoxification. In the process of performing its essential role in metabolism and detoxification, especially as regards exogenous agents, liver damage may occur. Common causes of liver damage include xenobiotics, alcohol consumption, malnutrition, infection, anemia and medications (Mroueh et al., 2004). Liver toxicity induced by chemicals is a well recognized problem (Kalantari and Valizadeh, 2000). According to Satoh (1991), after acute exposure, lipid accumulation in the hepatocytes, cellular necrosis or hepatobiliary dysfunction usually occurs, whereas cirrhosis or neoplastic changes are considered to be the results of chronic exposure. Navarro and Senior (2006) defined hepatotoxicity as injury to the liver that is associated with impaired liver function caused by exposure to drugs or noninfectious agents.

Hepatitis is one of the most prevalent diseases in the world and drug related hepatotoxicity is the leading cause of acute liver failure among patients referred for liver transplantation (Lee, 2005; Wang et al., 2008). Hepatic problems are responsible for a significant number of liver transplantations and deaths recorded worldwide and available therapeutic options are very limited (Akindele et al., 2010). In most cases of drug induced hepatotoxicity, there is no effective treatment other than cessation of drug use and general supportive care with the possible use of N-acetylcysteine after acetaminophen overdose and intravenous carnitine for valproate induced mitochondrial injury (Navarro and Senior, 2006; Bohan et al., 2001; Polson and Lee, 2005). Silymarin, a flavonolignan from “milk thistle” (*Silybum marianum*) plant has clinical applications in alcoholic liver diseases, liver cirrhosis, *Amanita* mushroom poisoning, viral hepatitis, toxic and drug-induced liver disease and in diabetic patients, with non-traditional use in the protection of other organs in addition to the liver also being advocated (Pradhan and Girish, 2006).

Due to the wide range of drugs that can cause hepatotoxicity (including antibiotic, antitubercular, antiviral, anticonvulsant, analgesic (non-steroidal anti-inflammatory drugs [NSAIDs] and acetaminophen), antihypertensive, antipsychotic, antidepressant and oral contraceptive agents) and the increasing incidence and fatality of drug-induced hepatotoxicity, efforts are ongoing worldwide to discover new drugs, especially from natural products, or find relevant uses for old orthodox drugs.

Exaggerated calcium influx into cells is an important signal that may lead to cell death and a number of hepatotoxic effects of drugs is associated with increase in intracellular calcium (Thomas and Reed, 1989; Nicotera et al., 1992; Farghali et al., 2000). Kristian and Siesjo (1998) reported that calcium as a triggering factor has also been associated with ischemic cell death. According to Nicotera et al. (1992) and Gasbarrini et al. (1992), a number of hepatocyte injuries is associated with an elevation of intracellular calcium and that calcium signaling plays a pivotal role in the cascade of events that leads to cell injury. Based on these facts, calcium antagonism has been explored in the management of hepatotoxicity.

In respect of profiling hepatoprotective actions of calcium channel blockers (CCBs), Farghali et al. (2000) investigated the effects of CCBs on *tert*-butyl hydroperoxide (TBH) induced liver injury using isolated perfused rat hepatocytes. The authors concluded that CCBs (verapamil and diltiazem) exhibited hepatoprotective properties, in hepatocyte oxidative injury, accompanied by a decrease in ATPase activity, which suggests normalization of Ca^{2+}_i after TBH intoxication. Sippel et al. (1993) demonstrated the modulatory action of some CCBs on impaired hepatocyte calcium homeostasis induced with diamidinothionaphthene (DAMTP). Landon et al. (1986) measured calcium in liver homogenates and scored tissues for centrilobular necrosis 24 h after administration of hepatotoxic doses of several chemicals

in vivo. Carbon tetrachloride, chloroform, dimethylnitrosamine, thioacetamide and acetaminophen all caused massive increase in hepatocellular calcium content and produced pericentral necrosis. Administration of calcium entry blockers (nifedipine, verapamil or chlorpromazine) 1 h before or 7 h after the hepatotoxins significantly attenuated increase in cellular calcium content and necrosis, thus demonstrating protective effect against chemical injury in the liver *in vivo*. Kalantari and Valizadeh (2000) investigated the protective effect of nifedipine against acetaminophen overdose (700 mg/kg) induced hepatotoxicity in mice. In the study, peak hepatoprotective activity was produced by nifedipine at the dose of 500 mg/kg.

The aim of this study was to investigate the effect of subclinical, clinical and supraclinical doses of CCBs (nifedipine, verapamil and diltiazem) on isoniazid-rifampicin combination, azidothymidine (zidovudine) and erythromycin-induced hepatotoxicity in rats.

MATERIALS AND METHODS

Drugs and chemicals

Zidovudine (Aurobindo Pharma, Hyderabad, India), rifampicin (Mekophar Pharmaceutical, Ho Chi Minh City, Vietnam), isoniazid (Pfizer Pharmaceuticals, Lagos, Nigeria), erythromycin stearate (Aurochem Pharmaceuticals Pvt Ltd, Mumbai, India), verapamil (APS/Berk

Pharmaceutical Ltd, Eastbourne, England), nifedipine (Gemini Pharmaceuticals, Lagos, Nigeria), diltiazem (Sanofi-Aventis, Milan, Italy), silymarin and hexobarbital (Sigma-Aldrich, St Louis, USA).

Animals

The animals used in this study, 4-6 weeks old male and female albino rats weighing between 150-200 g, were obtained from the Laboratory Animal Center of the College of Medicine, University of Lagos, Nigeria. The animals were housed in polypropylene cages and kept in standard environmental conditions having access to standard rodent feed (Livestock Feeds PLC, Lagos, Nigeria) and clean water *ad libitum*. Rats were acclimatized for two weeks before the experimental procedures began.

The experimental procedures were carried out in compliance with the United States National Academy of Sciences Guide for the Care and Use of Laboratory Animals (Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011).

Experimental design

Isoniazid-rifampicin-induced hepatotoxicity model

Rats were randomly allotted to 12 different treatment groups (n = 5) as shown in Table 1.

Table 1: Treatment groups in the isoniazid-rifampicin-induced hepatotoxicity model

Group no.	Treatment
Group 1	normal saline 10 ml/kg <i>p.o.</i>
Group 2	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i>
Group 3	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + silymarin 50 mg/kg <i>p.o.</i>
Group 4	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + nifedipine 0.17 mg/kg <i>p.o.</i> (subclinical dose)
Group 5	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + nifedipine 0.86 mg/kg <i>p.o.</i> (clinical dose)
Group 6	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + nifedipine 4.29 mg/kg <i>p.o.</i> (supraclinical dose)
Group 7	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + verapamil 0.86 mg/kg <i>p.o.</i> (subclinical dose)
Group 8	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + verapamil 4.30 mg/kg <i>p.o.</i> (clinical dose)
Group 9	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + verapamil 21.43 mg/kg <i>p.o.</i> (supraclinical dose)
Group 10	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + diltiazem 0.68 mg/kg <i>p.o.</i> (subclinical dose)
Group 11	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + diltiazem 3.43 mg/kg <i>p.o.</i> (clinical dose)
Group 12	isoniazid-rifampicin 100 mg/kg each <i>i.p.</i> + diltiazem 17.14 mg/kg <i>p.o.</i> (supraclinical dose)

Treatment was carried out for 21 days. The hepatotoxicants and therapeutic interventions were given concurrently (Balakrishnan et al., 2010).

The clinical dose was calculated as the average of the range of doses used for the indications of the CCBs. The subclinical dose was 1/5th of the clinical dose while the supraclinical dose was 5 times the clinical dose.

Zidovudine-induced hepatotoxicity model

Treatment groups in this test are as outlined in Table 1 except that zidovudine 800 mg/kg *p.o.* was used in place of isoniazid-rifampicin combination to induce hepatotoxicity. Administration of drugs was carried out for 28 days (Tikoo et al., 2008).

Erythromycin-induced hepatotoxicity model

In this model erythromycin stearate 100 mg/kg *p.o.* was used to induce hepatotoxicity and the treatment period in respect of the groups earlier outlined in Table 1 was 14 days (Abdel-Hameid, 2007).

Hexobarbitone-induced hypnosis test

A day before the last administration in respect of the models (20th, 27th and 13th day for the isoniazid-rifampicin, zidovudine and erythromycin models respectively), rats were subjected to the hexobarbitone-induced hypnosis test for the indirect assessment of the level of cytochrome P450 metabolizing enzyme activity. Each rat in the different groups received hexobarbitone 60 mg/kg *i.p.* Rats were then placed on their backs in separate observation chambers and the duration of loss of the righting reflex (starting at the time of hexobarbitone injection until they regained their righting reflexes) were recorded. The recovery of righting reflex was confirmed if the animal, when gently placed on its back again, rights itself within one minute (Vogel and Vogel, 1997; Akindele and Adeyemi, 2010). The duration of sleep (min) was then recorded for each animal.

Assessment of parameters

Two hours after the administration of drugs on the last day of treatment for each of the models (21st, 28th and 14th day for the isoniazid-rifampicin, zidovudine and erythromycin models respectively), blood samples were collected from each of the rats by retro-orbital artery bleeding into plain sample bottles. Serum separated out by centrifugation at 3000 rpm at 25 °C for 15 min was used for the estimation of relevant biochemical parameters. After blood collection, the animals were sacrificed by cervical dislocation and laparatomized for the harvest of liver. A slice of approximately 1/3rd of the liver of each rat was processed for estimation of *in vivo* antioxidant indices while the remaining 2/3rd was fixed in 10 % formo-saline for histopathological assessment.

Biochemical analysis

Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total cholesterol, total bilirubin (TBILI), albumin and total protein were estimated using Roche and Cobas commercial kits and Roche/Hitachi 904 automated analyzer.

Measurement of antioxidant indices

Measurement of antioxidant indices in liver samples including catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), reduced glutathione (GSH) and malondialdehyde (MDA) was done according to established procedures (Soon and Tan, 2002; Habbu et al., 2008) Total protein was determined using the Biuret method (Gornall et al., 1949).

Histopathological assessment

The various tissues obtained from experimental animals fixed in 10 % formo-saline were dehydrated in graded alcohol, embedded in paraffin, and cut into 4-5 µm thick sections. Hematoxylin-eosin was used to stain the sections for photomicroscopic assessment using a Model N-400ME photomicroscope (CEL-TECH Di-

agnostics, Hamburg, Germany). Slides were examined using the $\times 40$, $\times 100$, and $\times 400$ objectives (Galigher and Kozloff, 1971; Habbu et al., 2008).

Statistical analysis

Results are expressed as mean \pm SEM. Data were analyzed using One-way ANOVA followed by Dunnett's multiple comparison test using GraphPad Prism 5 (GraphPad Software Inc., CA, USA). Values were considered significant when $P < 0.05$.

RESULTS

Isoniazid-rifampicin-induced hepatotoxicity model

Biochemical parameters

Isoniazid-rifampicin significantly ($P < 0.001$) increased the level of AST, ALT and ALP while significantly ($P < 0.001$) reducing the level of total protein and albumin (Table 2). Silymarin significantly ($P < 0.05$, 0.001) reduced the level of AST and increased the level of total protein compared with isoniazid-rifampicin alone treated group of animals. Nifedipine at all doses administered (subclinical, 0.17 mg/kg *p.o.*; clinical, 0.86 mg/kg *p.o.*; and supraclinical, 4.23 mg/kg *p.o.*) significantly ($P < 0.05$, 0.01, 0.001) reduced the level of AST and total bilirubin while increasing the level of total protein and albumin compared with the isoniazid-rifampicin group, with peak effect observed at the clinical dose. Verapamil at the clinical (4.29 mg/kg, *p.o.*) and supraclinical (21.43 mg/kg, *p.o.*) doses significantly ($P < 0.05$) reduced the level of AST, ALT and ALP while increasing the level of total protein and direct bilirubin compared with isoniazid-rifampicin group. There was an increase in total cholesterol at the subclinical dose (0.86 mg/kg, *p.o.*) when compared to the hepatotoxicant group. Diltiazem intervention significantly ($P < 0.05$) reduced the levels of AST, ALT and ALP while increasing the level of total protein compared with isoniazid-rifampicin alone

treated group, with effects being most pronounced at the clinical (3.43 mg/kg, *p.o.*) and supraclinical (17.13 mg/kg, *p.o.*) doses (Table 2).

In vivo antioxidant indices

Isoniazid-rifampicin significantly ($P < 0.05$, 0.01) reduced the levels of GSH, SOD, CAT and total protein with increase in the level of MDA when compared to rats of the control group (Table 3). Silymarin significantly ($P < 0.05$, 0.01) increased the level of GSH and reduced the level of MDA relative to the isoniazid-rifampicin only treated group. Co-administration of the antitubercular drugs with nifedipine significantly ($P < 0.05$, 0.01) reduced the level of MDA, at all the treatment doses, compared to the group of rats receiving isoniazid-rifampicin alone. However, peak effect was observed at the supraclinical dose (4.29 mg/kg, *p.o.*). At this dose, nifedipine also significantly ($P < 0.01$) reversed the reduction in GSH level induced by isoniazid-rifampicin. Verapamil and diltiazem significantly ($P < 0.001$) reduced the level of MDA compared with isoniazid-rifampicin only treated group, with peak effect produced at the clinical doses of 4.29 mg/kg and 3.43 mg/kg respectively (Table 3).

Hexobarbitone-induced hypnosis test

Isoniazid-rifampicin combination significantly ($P < 0.01$) increased the duration of sleep compared with the control group. Silymarin and nifedipine at the supraclinical dose (4.29 mg/kg, *p.o.*) significantly reduced the duration of sleep compared with the isoniazid-rifampicin alone treated group (Table 4). Verapamil and diltiazem at the various doses used did not elicit any significant effect ($P > 0.05$) on duration of sleep compared to the hepatotoxicant group.

Table 2: Effect of calcium channel blockers (nifedipine, verapamil and diltiazem) on serum biochemical parameters in isoniazid-rifampicin combination-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	TP (g/L)	ALB (g/L)	TB (μmol/L)	DB (μmol/L)	TC (mmol/L)
Control	(10 ml/kg)	65.60±4.05	13.20±0.80	9.60±1.15	81.00±2.75	35.80±3.82	6.40±0.67	5.00±2.23	1.64±0.15
INH-RIF	100	101.60±4.95 ³	22.80±1.15 ³	17.20±1.35 ³	51.20±2.79 ³	23.80±1.65 ³	8.80±0.58	4.80±0.83	1.26±0.05
SIL + INH-RIF	50/100	79.20±8.60 ^a	16.20±1.35	13.80±0.73 ¹	67.20±0.80 ^{2,γ}	24.20±1.65 ²	7.20±0.58	4.80±0.37	1.34±0.05
NIF + INH-RIF	0.17/100	80.40±8.93 ^a	19.60±1.47 ²	13.40±1.16	63.80±2.69 ^{3,β}	30.20±0.66 ^β	6.20±0.73 ^a	3.40±0.89	1.48±0.11
	0.86/100	75.00±2.09 ^β	12.60±1.28	10.40±0.50	66.80±2.15 ^{2,γ}	30.20±0.66 ^β	9.00±0.83	3.00±1.22	1.46±0.10
	4.29/100	74.80±7.44 ^β	14.20±0.96	16.40±3.31 ³	65.21±2.16 ^{3,γ}	29.00±1.09 ^a	9.60±0.40 ²	3.00±0.54	1.64±0.15
VER + INH-RIF	0.86/100	86.80±4.96 ¹	13.40±0.87	14.60±0.81 ²	50.40±0.74 ³	25.20±1.66 ²	7.00±0.63 ²	4.20±0.83	1.70±0.12 ^a
	4.30/100	85.20±6.62	16.60±1.66 ^γ	11.40±0.81 ^β	49.20±1.85 ³	28.20±1.11	9.40±0.92 ²	5.60±0.40 ^a	1.44±0.11
	21.43/100	73.40±3.94 ^β	15.40±0.40 ^γ	12.20±0.96 ^β	64.60±1.53 ^{3,γ}	24.60±0.74 ²	10.40±0.40	5.00±0.54 ^a	1.28±0.11
DIL + INH-RIF	0.68/100	87.00±5.86 ¹	15.00±0.40 ^γ	14.00±0.90 ^β	63.00±3.56 ^{3,α}	28.80±0.91	9.60±0.67	4.40±0.50	1.56±0.20
	3.43/100	70.80±6.62 ^γ	14.00±0.70 ^γ	11.40±0.67 ^β	63.60±2.60 ^{3,β}	24.60±0.74 ²	9.60±0.40	4.20±0.58	1.44±0.23
	17.14/100	72.00±1.94 ^β	12.20±1.75 ^γ	13.00±1.70	63.80±2.17 ^{3,β}	24.40±1.86 ²	6.80±0.80	5.20±0.66	1.60±0.56

Data are expressed as mean ± S.E.M. (n = 5). ¹P < 0.05, ²P < 0.01, ³P < 0.001 vs. control; ^aP < 0.05, ^βP < 0.01, ^γP < 0.001 vs. isoniazid-rifampicin combination (One-way ANOVA followed by Dunnett's multiple comparison test)

Table 3: Effect of nifedipine, verapamil and diltiazem on *in vivo* antioxidant indices in liver samples in isoniazid-rifampicin combination-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	GSH (U/mg protein)	SOD (U/mg protein)	CAT (U/mg protein)	GPx (U/mg protein)	MDA (U/mg protein)	Total protein (mg)
Control	(10 ml/kg)	5.41±1.89	13.25±2.56	22.26±1.47	4.49±0.37	0.27±0.09	74.15±3.36
INH-RIF	100	1.04±0.23 ¹	1.21±0.14 ³	5.82±1.96 ³	0.58±0.20	1.03±0.13 ³	27.09±2.51 ³
SIL + INH-RIF	50/100	3.39±0.65	2.53±0.72 ³	8.86±4.24 ²	0.49±0.21	0.09±0.02 ^γ	36.21±7.84 ²
NIF + INH-RIF	0.17/100	2.20±0.26	1.65±0.43 ³	9.01±1.79 ²	0.52±0.13	0.15±0.06 ^γ	30.05±5.22 ³
	0.86/100	2.25±0.36	2.22±0.81 ³	9.26±3.04 ²	0.69±0.25	0.11±0.01 ^γ	28.85±7.66 ³
	4.29/100	4.46±1.35 ^β	1.87±0.65 ³	4.70±1.18 ³	0.38±0.04	0.07±0.11 ^γ	33.66±8.99 ³
VER + INH-RIF	0.86/100	2.04±0.37 ¹	1.56±0.68 ³	9.57±3.85 ¹	0.79±0.22	0.21±0.03 ^γ	21.65±1.83 ²
	4.30/100	2.43±0.48	1.91±0.76 ³	9.57±3.86	0.60±0.23	0.17±0.16 ^γ	68.54±14.08
	21.43/100	1.82±0.42 ¹	2.89±1.22 ³	15.19±6.5 ³	0.91±0.38	0.22±0.04 ^γ	39.09±13.26
DIL + INH-RIF	0.68/100	2.70±0.80	2.09±1.08 ³	6.22±2.13 ³	0.65±0.33	0.09±0.00 ^γ	38.27±10.95 ³
	3.43/100	1.40±0.16 ¹	1.94±0.54 ³	6.02±1.68 ³	0.63±0.17	0.05±0.16 ^γ	51.81±4.02 ²
	17.14/100	2.77±0.48	2.26±0.55 ³	8.40±1.84 ²	12.5±1.40	0.17±0.03 ^γ	12.50±1.40 ³

Data are expressed as mean ± S.E.M. (n = 5). ¹P < 0.05, ²P < 0.01, ³P < 0.001 vs. control; ^βP < 0.01, ^γP < 0.001 vs. isoniazid-rifampicin combination (One-way ANOVA followed by Dunnett's multiple comparison test)

Table 4: Effect of nifedipine, verapamil and diltiazem on duration of sleep in hexobarbitone-induced hypnosis test in isoniazid-rifampicin combination-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	Duration of sleep (min)
Control	(10 ml/kg)	6.60±2.75
INH-RIF	100	16.00±3.11 ²
SIL + INH-RIF	50/100	6.62±1.22 ^β
NIF + INH-RIF	0.17/100	13.75±2.69 ¹
	0.86/100	11.25±1.57
	4.29/100	10.63±3.67 ^α
VER + INH-RIF	0.86/100	13.13±3.43
	4.30/100	14.88±3.09
	21.43/100	12.25±2.22
DIL + INH-RIF	0.68/100	8.87±0.87 ²
	3.43/100	8.00±1.29 ²
	17.14/100	7.62±1.48 ²

Data are expressed as mean ± S.E.M. (n = 5). ¹P < 0.05, ²P < 0.01 vs. control; ^αP < 0.05, ^βP < 0.01 vs. isoniazid-rifampicin combination (One-way ANOVA followed by Dunnett's multiple comparison test)

Zidovudine-induced hepatotoxicity model

Biochemical parameters

Significant ($P < 0.01$, 0.001) increase in the levels of AST, ALT, ALP and total bilirubin but significant ($P < 0.01$) reduction in the level of total protein were observed in the zidovudine treated rats compared to control (Table 5). Silymarin significantly ($P < 0.05$, 0.01) reversed the effect of zidovudine on ALP and total bilirubin. Nifedipine at the clinical dose (0.86 mg/kg, *p.o.*) and supraclinical dose (4.29 mg/kg, *p.o.*) produced significant ($P < 0.05$, 0.01) reduction in the levels of AST and ALP compared to the zidovudine treated group. Verapamil at the supraclinical dose (21.43 mg/kg, *p.o.*) significantly ($P < 0.05$, 0.01) reduced the level of AST and increased the level of total protein relative to the zidovudine only group. In respect of diltiazem, there was significant ($P < 0.05$, 0.01 , 0.001) reduction in the levels of AST and total bilirubin while the level of total protein was significantly ($P < 0.05$,

0.01) increased compared to the zidovudine treated rats, at all doses used. However, peak protective effect was elicited at the subclinical dose, 0.68 mg/kg, *p.o.* (Table 5).

In vivo antioxidant indices

Zidovudine (800 mg/kg, *p.o.*) caused significant ($P < 0.01$) reductions in the levels of GSH, SOD, CAT, GPx and total protein in liver samples but the level of MDA was significantly ($P < 0.001$) increased compared to control (Table 6). Silymarin (50 mg/kg, *p.o.*) significantly ($P < 0.05$, 0.01 , 0.001) reversed the effect of zidovudine on these parameters especially as it relates to GSH, CAT and MDA. Nifedipine at the subclinical dose (0.17 mg/kg, *p.o.*), clinical dose (0.86 mg/kg, *p.o.*) and supraclinical dose (4.23 mg/kg, *p.o.*) reversed the elevation in the levels of MDA produced by zidovudine, with peak protective effect observed at the clinical dose. However, the level of CAT observed with nifedipine at the clinical and supraclinical doses were significantly ($P < 0.05$, 0.01) lower when compared with the zidovudine only treated rats. Verapamil at all doses (subclinical, 0.86 mg/kg; clinical, 4.29 mg/kg; and supraclinical, 21.43 mg/kg, *p.o.*) significantly ($P < 0.01$, 0.001) reversed the elevation of MDA level produced by zidovudine. Verapamil also significantly ($P < 0.05$) increased the levels of SOD at the clinical dose but there was a significant ($P < 0.01$) reduction in CAT level at the supraclinical dose compared to zidovudine. Diltiazem at the supraclinical dose (4.23 mg/kg, *p.o.*) significantly ($P < 0.05$, 0.01) increased zidovudine diminished level of GSH, with a reversal of the increased level of MDA observed with zidovudine (Table 6).

Table 5: Effect of calcium channel blockers (nifedipine, verapamil and diltiazem) on serum biochemical parameters in zidovudine-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	TP (g/L)	ALB (g/L)	TB (µmol/L)	DB (µmol/L)	TC (mmol/L)
Control	(10 ml/kg)	65.60±4.05	13.20±0.80	12.00±1.15	81.00±2.75	35.80±3.82	6.40±0.67	5.00±1.00	1.64±0.15
ZID	800	144.00±10.30 ³	28.80±2.55 ²	40.00±4.62 ³	49.20±5.86 ²	27.40±2.35	12.60±0.92 ³	3.20±0.37	1.38±0.09
SIL + ZID	50/800	113.80±8.60 ³	20.00±2.44	26.40±26.60 ^{2,α}	62.40±2.61	27.60±2.33	7.40±1.03 ^β	3.00±0.44	1.56±0.10
NIF + ZID	0.17/800	137.60±8.93 ³	27.00±2.93 ²	37.20±3.31 ³	62.80±5.84	24.60±2.35 ¹	13.20±1.15 ³	3.20±0.37	1.36±0.06
	0.86/800	85.80±4.40 ^β	28.80±3.91 ²	24.80±4.48 ^{1,α}	55.00±6.63 ²	28.00±2.19	9.00±0.83	3.40±0.54	1.46±0.14
	4.29/800	112.40±8.58 ^{2,α}	20.20±1.42	31.00±3.31 ³	50.40±6.63 ²	28.00±2.19	9.00±0.83	3.00±0.44	1.56±0.22
VER + ZID	0.86/800	130.60±4.47 ³	25.60±2.61 ²	34.20±3.66 ³	61.00±8.47 ¹	32.60±4.72	8.40±1.15	2.80±0.37	1.60±0.17
	4.30/800	122.80±12.90 ³	27.40±1.60 ³	32.60±4.46 ³	61.20±5.05	22.80±1.65 ¹	9.40±1.32	3.80±0.66	1.50±0.20
	21.43/800	80.20±2.97 ^γ	26.40±2.99 ²	34.60±4.10 ³	71.80±4.34 ^α	28.80±1.59	10.60±1.43 ¹	3.20±0.37	1.32±0.10
DIL + ZID	0.68/800	75.60±4.16 ^γ	25.60±2.83 ²	34.60±3.25 ³	70.80±3.30 ^β	29.00±2.09	8.60±0.97 ^α	3.60±0.50	1.84±0.22
	3.43/800	89.60±6.70 ^γ	28.20±3.20 ³	33.40±2.44 ³	67.00±3.53 ^α	27.40±3.05	10.00±0.70 ¹	3.60±0.51	1.26±0.16
	17.14/800	100.40±8.03 ^{1,β}	27.40±1.28 ²	35.60±3.61 ³	68.60±4.28 ^α	26.40±1.63	9.20±1.24	3.20±0.37	1.52±0.13

Data are expressed as mean ± S.E.M. (n = 5). ¹P < 0.05, ²P < 0.01, ³P < 0.001 vs. control; ^αP < 0.05, ^βP < 0.01, ^γP < 0.001 vs. zidovudine (One-way ANOVA followed by Dunnett's multiple comparison test)

Table 6: Effect of nifedipine, verapamil and diltiazem on *in vivo* antioxidant indices in liver samples in zidovudine-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	GSH (U/mg protein)	SOD (U/mg protein)	CAT (U/mg protein)	GPx (U/mg protein)	MDA (U/mg protein)	Total protein (mg)
Control	(10 ml/kg)	5.41±1.89	13.25±2.56	22.26±1.47	4.49±0.37	0.27±0.09	74.15±3.36
ZID	800	0.78±0.12 ²	5.59±1.18 ²	12.91±1.46 ³	1.75±0.37 ²	1.20±0.11 ³	29.72±5.16 ²
SIL + ZID	50/800	4.36±0.83 ^α	6.25±0.83 ²	20.21±2.46 ^β	2.02±0.36 ²	0.30±0.02 ^γ	59.86±3.55 ²
NIF + ZID	0.17/800	0.73±0.23 ²	6.71±1.18 ¹	10.11±1.13 ³	2.16±0.32 ²	0.17±0.02 ^γ	48.27±4.58 ²
	0.86/800	1.51±0.52 ¹	5.24±1.08 ²	3.58±0.79 ^{3,β}	1.64±0.33 ²	0.11±0.03 ^γ	74.15±20.35 ²
	4.29/800	2.30±0.43	4.23±0.56 ³	6.61±1.18 ^{3,α}	1.32±0.81 ³	0.47±0.13 ^γ	30.66±3.49 ³
VER + ZID	0.86/800	3.35±1.40	9.75±2.23 ¹	20.74±3.15	3.05±0.70	0.60±0.09 ^β	22.44±3.31 ³
	4.30/800	2.33±0.70	9.75±1.03 ^{1,α}	14.88±1.36	2.99±1.31	0.57±0.06 ^β	27.88±5.11 ³
	21.43/800	3.12±1.44	8.25±1.25	4.39±1.36 ^{3,β}	0.20±0.03 ²	0.48±0.18 ^γ	47.39±9.44 ²
DIL + ZID	0.68/800	3.69±0.60	6.31±0.53 ¹	8.17±1.33 ³	1.98±0.32	0.92±0.36	32.14±11.14 ¹
	3.43/800	2.68±0.39	7.75±10.25	10.25±2.89 ²	2.03±0.27	0.54±0.14	51.57±18.00 ³
	17.14/800	6.32±2.49 ^α	10.03±2.20	16.98±2.48	5.42±3.20	0.14±0.02 ^β	27.91±11.75 ¹

Data are expressed as mean ± S.E.M. (n = 5). ¹P < 0.05, ²P < 0.01, ³P < 0.001 vs. control; ^αP < 0.05, ^βP < 0.01, ^γP < 0.001 vs. zidovudine (One-way ANOVA followed by Dunnett's multiple comparison test)

Hexobarbitone-induced hypnosis test

Significant ($P < 0.01$) increase in the duration of sleep was observed in the zidovudine treated group of rats compared to the control group. Silymarin and the CCBs at all doses used did not significantly ($P > 0.05$) affect the duration of sleep compared to the zidovudine only group (Table 7).

Table 7: Effect of nifedipine, verapamil and diltiazem on duration of sleep in hexobarbitone-induced hypnosis test in zidovudine-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	Duration of sleep (min)
Control	(10 ml/kg)	6.60±2.75
ZID	800	23.20±3.48 ²
SIL + ZID	50/800	12.20±3.66
NIF + ZID	0.17/800	21.00±3.05 ¹
	0.86/800	12.80±3.83
	4.29/800	16.80±3.21
VER + ZID	0.86/800	21.80±5.51
	4.30/800	25.00±4.33 ¹
	21.43/800	13.00±3.67
DIL + ZID	0.68/800	15.40±2.52
	3.43/800	9.60±3.07
	17.14/800	13.80±5.97

Data are expressed as mean ± S.E.M (n = 5). ¹ $P < 0.05$, ² $P < 0.01$ vs. control (One-way ANOVA followed by Dunnett's multiple comparison test)

Erythromycin-induced hepatotoxicity model**Biochemical parameters**

As shown in Table 8, erythromycin caused a significant ($P < 0.01$, 0.001) increase in serum ALT and AST levels when compared to the control group. Silymarin produced a decrease in AST and ALT levels compared to the erythromycin group but the effect was only significant ($P < 0.01$) in respect of AST. Treatment with the CCBs reduced the elevated levels of AST and ALT but the effect was only significant ($P < 0.05$) in respect of AST. Nifedipine administered at the subclinical dose of 0.17 mg/kg pro-

duced the most pronounced effect with the effect of verapamil at the clinical dose of 4.30 mg/kg also being significant ($P < 0.05$). Erythromycin also caused a significant ($P < 0.001$) increase in serum ALP level compared to the control group. Silymarin and the CCBs produced significant reductions ($P < 0.001$) in ALP level compared to erythromycin. Diltiazem at the clinical dose of 3.43 mg/kg produced the most pronounced effect. Erythromycin had no significant effect ($P > 0.05$) on total protein compared to the control. Silymarin produced a significant ($P < 0.05$) reduction in the level of total protein compared to erythromycin. The CCBs did not produce any significant effect ($P > 0.05$) on total protein compared to the erythromycin group (Table 8). Erythromycin produced a significant ($P < 0.01$) increase in albumin level when compared to control. Silymarin produced a significant ($P < 0.05$) reduction in the level of albumin compared to erythromycin. The CCBs did not generally produce a significant effect on serum albumin compared to the erythromycin group except in the case of verapamil at the clinical dose of 4.30 mg/kg in which there was a significant ($P < 0.001$) reduction (Table 8). In respect of total bilirubin, direct bilirubin and cholesterol, there was no significant difference in comparing erythromycin with control and in comparing silymarin and the CCBs with erythromycin except in the case of verapamil at the subclinical dose of 0.86 mg/kg in which a significant ($P < 0.001$) increase in total bilirubin was produced compared to erythromycin (Table 8).

In vivo antioxidant indices

Erythromycin reduced the level of GSH compared to control but this effect was not significant ($P > 0.05$). Silymarin, verapamil at the subclinical dose of 0.86 mg/kg, and diltiazem at the clinical dose of 3.43 mg/kg reversed the effect of erythromycin by significantly ($P < 0.05$) increasing the level of

GSH. Nifedipine at all the doses used, verapamil at 4.30 and 17.40 mg/kg, and diltiazem at 0.68 and 17.14 mg/kg did not produce any significant effect on GSH level compared to erythromycin (Table 9). Erythromycin did not produce any significant effect ($P > 0.05$) on SOD, CAT, GPx, and MDA compared to control. Silymarin and the CCBs also did not produce any significant ($P > 0.05$) effect on these parameters relative to erythromycin (Table 9). Erythromycin increased the level of total protein in liver samples but this effect was not significant ($P > 0.05$) compared to the control. Compared to erythromycin, silymarin reduced the level of total protein but this effect was also not significant ($P > 0.05$). Nifedipine at the supraclinical dose of 4.29 mg/kg and verapamil at the clinical and supraclinical doses of 4.30 mg/kg and 17.30 mg/kg respectively, significantly ($P < 0.01, 0.001$) increased the total protein level compared to erythromycin. However, diltiazem at the clinical dose of 3.43 mg/kg significantly ($P < 0.05$) reduced the total protein level compared to erythromycin (Table 9).

Hexobarbitone-induced hypnosis test

In relation to control, erythromycin significantly ($P < 0.001$) increased the duration of sleep. Silymarin and the CCBs at all doses used significantly ($P < 0.001$) reduced the duration of sleep compared to erythromycin. The effect of the CCBs in preserving the metabolizing effect of cytochrome P450 enzymes on hexobarbitone was most pronounced for nifedipine at the subclinical dose of 0.17 mg/kg, for verapamil at the clinical dose of 4.30 mg/kg, and for diltiazem at the subclinical dose of 0.68 mg/kg (Table 10).

Histopathological assessment

Hepatotoxicants representative samples presented with cytoplasmic inclusions with frosted appearance of hepatocytes due to intracellular accumulation of material, and periportal hemorrhage with the observation of presence of blood around the portal tracts. Control, silymarin, and CCBs intervention representative samples generally presented as normal liver with hepatocytes arranged as plates radiating away from the central vein to the portal tracts. Representative photomicrographs are presented as Figures 1A-F.

Table 8: Effect of calcium channel blockers (nifedipine, verapamil and diltiazem) on serum biochemical parameters in erythromycin-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	TP (g/L)	ALB (g/L)	TB (μmol/L)	DB (μmol/L)	TC (mmol/L)
Control	(10 ml/kg)	50.00 ± 2.50	8.60 ± 0.40	18.80 ± 0.70	63.40 ± 4.30	29.60 ± 0.20	8.40 ± 0.20	4.00 ± 0.50	1.60 ± 0.20
ERT	100	78.80 ± 5.10 ¹	27.40 ± 3.80 ³	113.20 ± 4.10 ¹	68.00 ± 1.60	34.00 ± 1.40 ¹	7.40 ± 0.80	3.80 ± 0.80	2.00 ± 0.30
SIL + ERT	50/100	50.40 ± 7.10 ^β	18.40 ± 0.70	51.60 ± 4.90 ^{γ,2}	66.60 ± 3.60 ^α	29.20 ± 0.50 ^α	6.20 ± 1.00	2.40 ± 0.40	2.20 ± 0.10
NIF + ERT	0.17/100	55.40 ± 2.10 ^α	21.80 ± 3.40 ¹	39.00 ± 6.00 ^γ	65.60 ± 1.40	33.80 ± 0.50 ¹	6.20 ± 0.70	3.00 ± 0.50	2.30 ± 0.40
	0.86/100	68.40 ± 4.45	24.20 ± 3.90 ²	59.80 ± 11.70 ^{γ,3}	68.40 ± 1.70	30.60 ± 0.70	6.20 ± 1.00	2.80 ± 0.90	2.10 ± 0.30
	4.29/100	67.40 ± 5.60 ¹	21.60 ± 3.70 ¹	26.40 ± 4.00 ^γ	69.80 ± 3.80	31.40 ± 0.70	7.20 ± 0.70	2.80 ± 0.40	2.50 ± 0.40
VER + ERT	0.86/100	76.00 ± 4.70 ²	29.60 ± 5.10 ²	34.60 ± 3.50 ^γ	71.60 ± 1.70	32.00 ± 1.30	6.40 ± 0.70 ^γ	2.60 ± 0.40	2.50 ± 0.40
	4.30/100	57.40 ± 3.10 ^α	24.60 ± 5.90 ¹	35.20 ± 3.90 ^γ	70.40 ± 3.60	31.80 ± 1.30 ^γ	7.20 ± 0.20	2.60 ± 0.30	1.80 ± 0.20
	21.43/100	78.40 ± 6.70 ²	23.60 ± 4.30	27.60 ± 9.20 ^γ	66.20 ± 0.60	33.00 ± 1.10	7.00 ± 0.70	3.00 ± 0.60	2.50 ± 0.20
DIL + ERT	0.68/100	70.40 ± 3.30	29.00 ± 6.10 ²	34.80 ± 3.10 ^γ	75.60 ± 2.70 ¹	35.80 ± 1.20 ³	6.40 ± 0.80	3.20 ± 0.60	2.20 ± 0.40
	3.43/100	73.40 ± 5.70	25.40 ± 4.90 ¹	23.60 ± 5.70 ^γ	69.60 ± 2.80	32.80 ± 1.00	7.20 ± 1.00	3.20 ± 0.50	2.50 ± 0.30
	17.14/100	72.40 ± 12.70	20.00 ± 3.70	33.00 ± 7.80 ^γ	69.40 ± 1.90	31.20 ± 0.80	6.80 ± 0.80	3.40 ± 0.80	1.30 ± 0.10

Data are expressed as mean ± S.E.M. (n = 5). ¹P < 0.05, ²P < 0.01, ³P < 0.001 vs. control; ^αP < 0.05, ^βP < 0.01, ^γP < 0.001 vs. erythromycin (One-way ANOVA followed by Dunnett's multiple comparison test)

Table 9: Effect of nifedipine, verapamil and diltiazem on *in vivo* antioxidant indices in liver samples in erythromycin-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	GSH (U/mg protein)	SOD (units/mg protein)	CAT (units/mg protein)	GPx (units/mg protein)	MDA (units/mg protein)	Total protein (mg)
Control	(10 ml/kg)	1.80 ± 0.69	3.79 ± 0.73	14.31 ± 3.57	1.18 ± 0.23	0.30 ± 0.11	16.14 ± 1.54
ERT	100	0.59 ± 0.32	2.73 ± 1.15	12.86 ± 5.26	0.86 ± 0.36	0.13 ± 0.02	38.54 ± 8.06
SIL + ERT	50/100	2.19 ± 0.40 ^α	3.23 ± 0.48	11.60 ± 1.16	1.02 ± 0.15	0.34 ± 0.19	17.88 ± 3.31
NIF + ERT	0.17/100	0.79 ± 0.30	7.52 ± 1.70	21.44 ± 4.25	2.36 ± 0.53	0.14 ± 0.03	23.32 ± 3.11
	0.86/100	0.53 ± 0.18	8.20 ± 3.76	9.56 ± 1.36	2.57 ± 1.18	0.14 ± 0.06	32.42 ± 4.41
	4.29/100	1.02 ± 0.68	3.19 ± 0.78	10.08 ± 4.72	1.00 ± 0.24	0.18 ± 0.09	104.80 ± 21.94 ^{β,3}
VER + ERT	0.86/100	1.75 ± 0.36 ^α	3.35 ± 1.69	12.01 ± 4.19	1.05 ± 0.53	0.08 ± 0.03	55.11 ± 7.72 ¹
	4.30/100	0.85 ± 0.23	2.01 ± 0.75	8.50 ± 3.66	0.63 ± 0.24	0.12 ± 0.03	94.70 ± 21.36 ^{β,3}
	21.43/100	0.44 ± 0.06	1.33 ± 0.39	4.32 ± 0.95	0.42 ± 0.12	0.06 ± 0.01	127.00 ± 3.37 ^{γ,3}
DIL + ERT	0.68/100	1.97 ± 0.42	3.24 ± 0.22	9.12 ± 3.11	0.60 ± 0.12	0.27 ± 0.1	30.44 ± 4.97
	3.43/100	2.51 ± 0.52 ^α	3.24 ± 0.22	14.63 ± 1.16	1.02 ± 0.07	0.21 ± 0.1	18.10 ± 1.77 ^α
	17.14/100	1.66 ± 0.29	2.73 ± 0.95	15.48 ± 4.64	0.86 ± 0.3	0.18 ± 0.04	28.49 ± 6.13

Data are expressed as mean ± S.E.M. (n=5). ¹P < 0.05, ²P < 0.001 vs. control; ^αP < 0.05, ^βP < 0.01, ^γP < 0.001 vs. erythromycin (One-way ANOVA followed by Dunnett's multiple comparison test)




Figure 1: Representative photomicrographs of liver samples. **A.** control group (normal saline 10 ml/kg, *p.o.*) showing normal liver architecture; **B.** isoniazid-rifampicin group (100 mg/kg each, *p.o.*) showing cytoplasmic inclusions; **C.** Silymarin (50 mg/kg, *p.o.*) + isoniazid-rifampicin (100 mg/kg each, *p.o.*) group showing normal liver; **D.** Nifedipine (clinical dose; 0.86 mg/kg, *p.o.*) + isoniazid-rifampicin (100 mg/kg each, *p.o.*) group showing normal liver; **E.** Zidovudine (800 mg/kg, *p.o.*) group showing periportal hemorrhage; **F.** Verapamil (clinical dose; 4.30 mg/kg, *p.o.*) + zidovudine (800 mg/kg, *p.o.*) group showing normal liver ($\times 400$)

Table 10: Effect of nifedipine, verapamil and diltiazem on duration of sleep in hexobarbitone-induced hypnosis test in erythromycin-induced hepatotoxicity in rats

Groups	Dose (mg/kg)	Duration of sleep (min)
Control	(10 ml/kg)	19.20 ± 1.63
ERT	100	28.20 ± 0.92 ³
SIL + ERT	50/100	10.60 ± 1.17 ^{y,3}
NIF + ERT	0.17/100	6.20 ± 0.58 ^{y,3}
	0.86/100	12.40 ± 1.03 ^{y,3}
	4.29/100	15.60 ± 0.98 ^y
VER + ERT	0.86/100	18.20 ± 1.69 ^y
	4.30/100	10.25 ± 1.85 ^{y,2}
	21.43/100	15.00 ± 2.89 ^y
DIL + ERT	0.68/100	6.67 ± 0.88 ^{y,2}
	3.43/100	14.67 ± 1.67 ^β
	17.14/100	13.00 ± 4.12 ^y

Data are expressed as mean ± S.E.M. (n=5). ²P < 0.01, ³P < 0.001 vs. control; ^βP < 0.01, ^yP < 0.001 vs. erythromycin (One-way ANOVA followed by Dunnett's multiple comparison test)

DISCUSSION

Drug-induced liver injury is a potential complication of nearly every prescribed medication and many fatal and near-fatal drug reactions occur each year (Kaplowitz, 1992; Zimmerman and Maddrey, 1993; Farrell, 1994; Lee, 1995). According to Pandit et al. (2012), more than 900 drugs, toxins and herbs have been reported to cause liver injury, and drug-induced liver injury is responsible for 5 % of all hospital admissions and 50 % of all acute liver failures. More than 75 % of cases of idiosyncratic drug reactions result in liver transplantation or death (Ostapowicz et al., 2002). Drug-induced liver injury is reported to be the most common reason for drug withdrawal from the market (Pandit et al., 2012). With increasing morbidity and mortality arising from drug-induced liver injury, a lot of attention is being devoted worldwide to understanding the mechanistic basis of drug-induced hepatotoxicity, strategy for management, and search for drugs (complementary or orthodox; natural or synthetic; old or new) that may ameliorate or reverse drug-induced liver injury by chemically or therapeutically diverse

agents. Among the numerous drugs reputed to induce hepatotoxicity are the antitubercular drugs isoniazid and rifampicin, antiviral drug zidovudine, and antibiotic erythromycin.

Isoniazid and rifampicin are first-line anti-tuberculosis chemotherapeutic agents that have been associated with hepatotoxicity. A major metabolic pathway of isoniazid is acetylation to acetylisoniazid and subsequent hydrolysis to acetylhydrazine and isonicotinic acid (Tostmann et al., 2008). Acetylhydrazine is either hydrolyzed to hydrazine or acetylated to diacetylhydrazine (Ellard and Gammon, 1976; Mitchell et al., 1976). Hydrazine has been suggested as the toxic metabolite of isoniazid responsible for its hepatotoxicity (Gent et al., 1992; Sarich et al., 1996). Hydrazine is known to cause irreversible cellular damage (Tostmann et al., 2008) and a study in rat liver microsomes showed that nitrogen-centered radicals are formed during hydrazine metabolism which possibly participates in the hepatotoxicity process (Noda et al., 1985). Rifampicin undergoes desacetylation to desacetyl rifampicin and hydrolysis to produce 3-formylrifampicin (Acocella and Conti, 1980; Holdiness, 1984). The mechanism of rifampicin-induced hepatotoxicity is unknown (Tostmann et al., 2008) and there is no evidence for the presence of toxic metabolites (Westphal et al., 1994). However, rifampicin is a potent inducer of hepatic CYP450 and induction of isoniazid hydrolase results in increased hydrazine production when rifampicin is combined with isoniazid resulting in higher toxicity (Blair et al., 1985; Sarma et al., 1986).

Zidovudine is a potent inhibitor of HIV replication and the first clinically approved drug for AIDS (Tikoo et al., 2008). Several antiretrovirals, including zidovudine, have been reported to cause fatal acute hepatitis (Pandit et al., 2012). Mechanisms that have been suggested for zidovudine-induced toxicity include alteration in liver mitochondrial DNA, alteration in oxidative phosphorylation coupling and changes in fine ultrastructure of liver mitochondrial (Tikoo et

al., 2008). Generation of reactive oxygen species (ROS), peroxide production and oxidative damage in mitochondria have been reported to play vital roles in zidovudine-induced toxicity (Majid et al., 1991; Tikoo et al., 2008).

Erythromycin is a commonly used antibiotic which induces severe liver injury and cardiovascular dysfunction both in humans and experimental animals at high doses (Adams, 1976; Pari and Murugan, 2004). As reported by Pessayre et al. (1985), overdoses of erythromycin led to occurrence of hepatitis, hepatic dysfunction, jaundice and necrosis of hepatocytes. Erythromycin is metabolized to reactive nitrosoalkane derivatives, which may be further metabolized to nitroso radicals which could be responsible for the degradation of phospholipids in the liver (Pessayre et al., 1985). The highly reactive nitrosoalkane derivative is normally detoxified by glutathione but excessive consumption of glutathione stores enables the reactive intermediate of erythromycin to destroy hepatic cells and other cells (Pessayre et al., 1985).

Clinical chemistry variables considered useful in identifying liver toxicity include ALT, AST, sorbitol dehydrogenase (SDA), glutamate dehydrogenase (GLDH), total bile acids (TBA), lactate dehydrogenase (LDH), ornithine carbonyltransferase (OCT) and unconjugated bilirubin (UBILI) (hepatocellular toxicity); TBA, ALP, gamma glutamyltransferase (GGT), 5'-nucleotidase (5-NT) and TBILI (hepatobiliary toxicity); and glutamate dehydrogenase (GLDH), lactate and OCT (mitochondrial toxicity; EMEA, 2008). According to EMEA (2008), total protein, albumin, triglycerides, cholesterol, glucose and blood urea nitrogen, activated partial thromboplastin time (APTT) and prothrombin time (PT) can be used as supplementary tests for hepatic synthetic functions. Liver disease is implicated in cases of elevated levels of AST, ALT, LDH, total and direct bilirubin, ALP, gamma-glutamyltranspeptidase, 5-NT, prothrombin time and diminution in

level of albumin, hepatic demethylation and galactose elimination (Cotran et al., 2005).

Generally, hepatotoxicity is associated with diminished activity of cytochrome P450 metabolizing enzymes. The hexobarbitone-induced hypnosis test is an indirect method of assessing the activity of this class of enzymes. Hepatic damage resulting in reduced metabolizing enzyme activity will cause increase in the duration of sleep. For example, it has been reported that paracetamol and CCl₄ induced hepatic injury decreased the activity of cytochrome P450 enzymes and the metabolic functional activity of hepatocytes, thus delaying barbiturate metabolism and excretion of phenobarbitone leading to prolongation of sleeping time (Girish et al., 2009; Girish and Pradhan, 2012). According to these authors, pretreatment with hepatoprotective phytochemicals restored the phenobarbitone-induced sleeping time in a dose-related fashion.

CCBs disrupt the movement of Ca²⁺ through calcium channels and are indicated for the treatment of hypertension, angina pectoris and arrhythmias. Nifedipine, a dihydropyridine, possesses high vascular selectivity like other members of its class and it is primarily used to reduce systemic vascular resistance and arterial pressure. Members of the dihydropyridines class are primarily used to treat hypertension. Verapamil is a non-dihydropyridine (phenylalkylamine class) relatively selective for the myocardium and less effective as a systemic vasodilator drug. It is used in the treatment of angina and arrhythmias. Diltiazem is also non-dihydropyridine (benzothiazepine class) intermediate in action between nifedipine and verapamil. It has both cardiac depressant and vasodilator actions. Due to the association of hepatotoxicity with disruption in calcium homeostasis, which may result in the activation of many membrane damaging enzymes like ATPases, phospholipases, proteases and endonucleases, disruption of mitochondrial metabolism and ATP synthesis and damage of microfilaments used to support cell structure (Singh

et al., 2011), attempts have been made in the past to investigate the modulatory actions of CCBs in drug-induced hepatotoxicity using mostly *in vitro* models. This study was designed to investigate the effect of subclinical, clinical and supraclinical doses of CCBs (nifedipine, verapamil and diltiazem) on isoniazid-rifampicin, zidovudine and erythromycin-induced hepatotoxicity in rats.

In this study, isoniazid-rifampicin, zidovudine and erythromycin significantly increased the levels of AST, ALT, ALP and total bilirubin while reducing the levels of total protein and albumin relative to control. Elevation in the level of AST and the liver specific ALT result from leakage from damaged tissues as a result of hepatocellular necrosis (Amacher, 2002; Ozer et al., 2008) while increase in ALP level is as a result of overproduction and release in blood due to hepatobiliary injury and cholestasis (Ramaiah, 2007). Hepatobiliary injury and cholestasis cause reduced hepatic clearance and increase in the level of total bilirubin (Dufour et al., 2001). Reduction in the level of albumin and total protein are consequence of decreased synthetic capacity as a result of hepatic dysfunction (Thapa and Walia, 2007). The standard drug used, silymarin, significantly reduced the level of AST and increased the level of total protein in the isoniazid-rifampicin model; reduced the level of ALP and total bilirubin in zidovudine model; and reduced the level of AST and ALP in the erythromycin model, compared with the hepatotoxicant group. In the isoniazid-rifampicin model, the CCBs across the doses significantly reduced the level of AST, ALT, ALP and total bilirubin, while increasing the level of total protein and albumin relative to the hepatotoxicant. Effect was most prominent at the subclinical and clinical doses for nifedipine; supraclinical dose for verapamil; and clinical and supraclinical doses for diltiazem. In the zidovudine model, nifedipine most prominently reduced the AST and ALP level at the clinical dose; verapamil most prominently reduced AST and increased

total protein at the supraclinical dose; while diltiazem at the subclinical dose most prominently reduced AST and total bilirubin while increasing total protein compared with the hepatotoxicant group. In the erythromycin model, nifedipine at the subclinical and supraclinical doses significantly reduced AST and ALP levels, respectively relative to the hepatotoxicant group. Verapamil across the doses significantly reduced the level of total bilirubin, AST and ALP, while for diltiazem there was significant reduction in ALP level at the clinical dose compared with the hepatotoxicant group. The action of the CCBs in reducing the level of liver enzymes and total bilirubin, while increasing the level of total protein and albumin suggests hepatoprotective activity in drug-induced liver injury.

In respect of the hexobarbitone-induced hypnosis test, all the hepatotoxic agents used significantly increased the duration of sleep compared to control suggesting reduction in the metabolism of the barbiturate as a result of inhibition of cytochrome P450 activity due to liver damage. Nifedipine at the supraclinical dose and silymarin significantly reduced the duration of sleep relative to the isoniazid-rifampicin only treated group. The effects of the CCBs and silymarin were not significant compared to the hepatotoxicant in the zidovudine model. In the erythromycin model, however, silymarin and the CCBs at all doses used significantly reduced the duration of sleep relative to the hepatotoxicant with effects being most prominent at the subclinical dose for nifedipine and diltiazem, and at the clinical dose for verapamil. The reduction in the duration of sleep by the CCBs relative to the hepatotoxicant groups suggest ability to protect the integrity of the liver and conserve the activity of the cytochrome P450 metabolizing enzymes.

Oxidative stress is implicated as a common pathologic mechanism contributing to the initiation and progression of hepatic damage in a variety of liver disorders (Girish et al., 2009). Mammalian cells contain endogenous antioxidant enzymes,

including superoxide dismutase (SOD), glutathione peroxidase and catalase (Saeed et al., 2005). The initial step in the detoxification process is the dismutation of oxygen radicals to hydrogen peroxide by SOD. Catalase protects cells from oxidative stress of hydrogen peroxide by its cleavage to water and oxygen (Ookhtens and Kaplowitz, 1998). Glutathione peroxidase facilitate the conjugation of hydrogen peroxide to glutathione (reduced) leading to the generation of water and oxidized glutathione (Saeed et al., 2005; Akindele et al., 2010). GSH is an important biomolecule against chemically induced toxicity and can participate in the elimination of reactive intermediaries by reduction of hydroperoxides in the presence of GSH dependent enzymes; it functions as a free radical scavenger, a generator of α -tocopherol and also an important role player in the maintenance of protein sulfhydryl group (Meister, 1984; Girish et al., 2009). Malondialdehyde is a useful index of lipid peroxidation being a major breakdown product of lipid peroxides. The engagement and overwhelming of antioxidant enzymes by free radicals result in the depletion of the antioxidant defenses and induction of lipid peroxidation evident in elevation of MDA level (Akindele et al., 2010). Isoniazid-rifampicin significantly reduced the level of GSH, SOD and CAT while increasing the level of MDA relative to control. Silymarin significantly reduced the level of MDA compared with the hepatotoxicant group. Nifedipine at the supraclinical dose significantly increased the level of GSH relative to the isoniazid-rifampicin only treated group. All the CCBs at all doses used significantly reduced the level of MDA relative to the hepatotoxicant group with the most prominent effect produced at the supraclinical dose for nifedipine and the clinical dose for verapamil and diltiazem. Zidovudine significantly reduced all *in vivo* antioxidants and increased MDA compared with the control group. Silymarin significantly elevated the level of GSH and CAT while reducing MDA compared to zidovudine. Nifedipine at the clinical dose did not

significantly affect the *in vivo* antioxidants except a significant reduction in CAT at the clinical and supraclinical doses relative to zidovudine. However, nifedipine at all doses used significantly reduced MDA level compared with zidovudine with the most prominent effect produced at the clinical dose. Verapamil at the clinical dose significantly increased the level of SOD but reduced CAT level at the supraclinical dose compared to the hepatotoxicant group. However, the drug at all doses used in this study significantly reduced MDA level relative to zidovudine with the most prominent effect produced at the supraclinical dose. Diltiazem at the supraclinical dose significantly increased GSH level but reduced GPx level relative to zidovudine with no significant effect on MDA. Erythromycin at the dose used in this study did not elicit significant changes in the level of antioxidants and MDA. Relative to erythromycin, however, silymarin, verapamil at the subclinical dose and diltiazem at the clinical dose all increased the level of GSH. The elevation of hepatotoxicants diminished *in vivo* antioxidants level and reduction in the level of MDA relative to isoniazid-rifampicin, zidovudine and erythromycin suggest that the CCBs counteracted lipid peroxidation and preserved the capacity of *in vivo* antioxidants in the liver.

Observations in the histopathological assessment of representative liver samples across the groups give further credence to the results obtained in the biochemical, antioxidant indices and hypnosis test determinations.

Although the CCBs used in this study demonstrated hepatoprotective activity at the supraclinical doses, it is suggested that the trial or use of this drugs in humans be restricted to the subclinical and clinical doses due to the side-effects associated with this class of drugs e.g. flushing, dizziness, headache, excessive hypotension, constipation, gingival overgrowth, edema, reflex tachycardia, excessive bradycardia, impaired electrical conduction/atrioventricular nodal block and depressed contractility.

CONCLUSION

The results obtained in this study suggest that the calcium channel blockers (nifedipine, verapamil and diltiazem) possess hepatoprotective activity in drug-induced hepatotoxicity and they may be beneficial at the sub-therapeutic and therapeutic doses in situations where stoppage of drug therapy as a result of induced hepatotoxicity may be critical to therapeutic outcome.

ACKNOWLEDGMENTS

The authors express their gratitude to Mr. M. Chijioke (Department of Pharmacology) and Mr. S.O. Adenekan (Department of Biochemistry) of the Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, and Mr. S. Ogunnowo of the Chemical Pathology Department, Lagos University Teaching Hospital, Lagos, Nigeria, for technical assistance rendered in the course of this work.

DECLARATION OF INTEREST

The authors declare that there is no conflict of interest in respect of this study. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES

- Abdel-Hameid NH. Protective role of dime-thyl diphenyl bicarboxylate (DDB) against erythromycin induced hepatotoxicity in male rats. *Toxicol in Vitro* 2007;21:618-25.
- Acocella G, Conti R. Interaction of rifampicin with other drugs. *Tubercle* 1980;61:171-7.
- Adams HR. Antibiotic-induced alterations of cardiovascular reactivity. *Fed Proc* 1976;35:1148-50.
- Akindele AJ, Adeyemi OO. Anxiolytic and sedative effects of *Byrsocarpus coccineus* Schum. and Thonn. (Connaraceae) extract. *Int J Appl Res Nat Prod* 2010;3: 28-36.
- Akindele AJ, Ezenwanebe KO, Anunobi CC, Adeyemi OO. Hepatoprotective and *in vivo* antioxidant effects of *Byrsocarpus coccineus* Schum. and Thonn. (Connaraceae). *J Ethnopharmacol* 2010;129:46-52.
- Amacher DE. A toxicologist's guide to biomarkers of hepatic response. *Hum Exp Toxicol* 2002;21:253-62.
- Balakrishnan BR, Sangameswaran B, Bhaskar VH. Effect of methanol extract of *Cuscuta reflexa* aerial parts on hepatotoxicity induced by antitubercular drugs in rats. *Int J Appl Res Nat Prod* 2010;3:18-22.
- Blair IA, Mansilla TR, Brodie MJ, Clare RA, Dollery CT, Timbrell JA et al. Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. *Hum Toxicol* 1985;4:195-202.
- Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. *Neurology* 2001;41:1405-9.
- Committee for the Update of the Guide for the Care and Use of Laboratory Animals. *Guide for the care and use of laboratory animals* (8th ed.). Washington, DC: National Academies Press, 2011.
- Cotran RS, Kumar V, Fausto N, Nelso F, Robbins SL, Abbas AK. *Robbins and Cotran Pathologic Basis of Disease*. St. Louis, Mo: Elsevier Saunders, 2005.
- Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis and monitoring. *Clin Chem* 2001;47:1133-5.
- Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. *J Pharmacokinetic Biopharm* 1976;4:83-113.

- EMA (European Medicines Agency). Non-clinical guideline on drug-induced hepatotoxicity. Committee for Medicinal Products for Human Use (CHMP), Doc. Ref. EMEA/CHMP/SWP/150115/2006, London, 24 January 2008.
- Farghali H, Kmonickova E, Lotkova H, Martinek J. Evaluation of calcium channel blockers as potential hepatoprotective agents in oxidative stress injury of perfused hepatocytes. *Physiol Res* 2000;49:261-8.
- Farrell GC. Drug-induced liver disease. Edinburgh, Scotland: Churchill Livingstone, 1994.
- Galigher AE, Kozloff EN. Essentials of practical microtechniques (2nd ed, p 77). Philadelphia, PA: Lea and Febiger, 1971.
- Gasbarrini A, Borle AB, Farghali H, Francavilla A, van Thiel D. Fructose protects rat hepatocytes from anoxic injury. *J Biol Chem* 1992;267:5745-52.
- Gent WL, Seifart HI, Parkin DP, Donald PR, Lamprecht JH. Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients. *Eur J Clin Pharmacol* 1992;43:131-6.
- Girish C, Pradhan SC. Hepatoprotective activities of picroliv, curcumin, and ellagic acid compared to silymarin on carbon-tetrachloride-induced liver toxicity in mice. *J Pharmacol Pharmacother* 2012;3:149-55.
- Girish C, Bidhan CK, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. *Fund Clin Pharmacol* 2009; 23:735-45.
- Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. *J Biol Chem* 1949;177: 751-66.
- Habbu PV, Shastry RA, Mahadevan KM, Joshi H, Das SK. Hepatoprotective and antioxidant effects of *Argyrea speciosa* in rats. *Afr J Tradit Complement Altern Med* 2008;5:158-64.
- Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. *Clin Pharmacokinet* 1984;9:511-44.
- Kalantari H, Valizadeh M. Nifedipine in the treatment of liver toxicity induced by acetaminophen overdose in mice. *Acta Med Iran* 2000;38:240-4.
- Kaplowitz N. Drug metabolism and hepatotoxicity. In: Kaplowitz N (ed). *Liver and biliary diseases* (pp 82-97). Baltimore: Williams and Wilkins, 1992.
- Kristian T, Siesjo BK. Calcium in ischemic cell death. *Stroke* 1998;29:705-18.
- Landon EJ, Naukam RJ, Sastry BVR. Effects of calcium channel blocking agents on calcium and centrilobular necrosis in the liver of rats treated with hepatotoxic agents. *Biochem Pharmacol* 1986;30:697-705.
- Lee WM. Drug-induced hepatotoxicity. *N Engl J Med* 1995;333:1118-27.
- Lee WM. Drug-induced acute liver failure in the United States 2005: results from the U.S. Acute Liver Failure Study Group. FDA-PhRMA-AASLD Hepatotoxicity Steering Committee meeting 28 January 2005 (accessed January 20, 2006, at <http://www.fda.gov/cder/livertox/presentations2005/WilliamLee.ppt>).
- Majid S, Khanduja KL, Gandhi RK, Kapur S, Sharma RR. Influence of ellagic acid on antioxidant defense system and lipid peroxidation in mice. *Biochem Pharmacol* 1991; 42:1441-5.

- Meister A. New aspects of glutathione biochemistry and transport-selective alteration of glutathione metabolism. *Nutr Rev* 1984;42:397-410.
- Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. *Ann Intern Med* 1976;84:181-92.
- Mroueh M, Saab Y, Riskallah R. Hepatoprotective activity of *Centaurium erythraea* on acetaminophen-induced hepatotoxicity in rats. *Phytother Res* 2004;18:431-3.
- Navarro VJ, Senior JR. Drug-related hepatotoxicity. *N Engl J Med* 2006;354:731-9.
- Nicotera P, Bellomo G, Orrenius S. Calcium-mediated mechanisms in chemically induced cell death. *Annu Rev Pharmacol Toxicol* 1992;32:449-70.
- Noda A, Noda H, Ohno K, Sendo T, Misaka A, Kanazawa Y et al. Spin trapping of a free radical intermediate formed during microsomal metabolism of hydrazine. *Biochem Biophys Res Commun* 1985;133:1086-91.
- Ookhtens M, Kaplowitz N. Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. *Semin Liver Dis* 1998;18:313-29.
- Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davron JT, Steven HB et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med* 2002;137:947-54.
- Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. *Toxicology* 2008;245:194-205.
- Pandit A, Sachdeva T, Bafna P. Drug-induced hepatotoxicity: A review. *J Appl Pharm Sci* 2012;02(05):233-43.
- Pari L, Murugan P. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. *Pharmacol Res* 2004;49:481-6.
- Pessayre D, Larrey D, Brentano FC, Benhamon JB. Drug interaction and hepatitis produced by some macrolide antibiotics. *Journal Antimicrob Chemother* 1985;16:181-94.
- Polson J, Lee WM. AASLD position paper: the management of acute liver failure. *Hepatology* 2005;41:1179-97.
- Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. *Indian J Med Res* 2006;124:491-504.
- Ramaiah SK. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. *Food Chem Toxicol* 2007;45:1551-7.
- Saeed SA, Urfy MZS, Ali TM, Khimani FW, Gilani A. Antioxidants: their role in health and disease. *Int J Pharmacol* 2005;1:226-33.
- Sarich TC, Youssefi M, Zhou T, Adams SP, Wall RA, Wright JM. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. *Arch Toxicol* 1996;70:835-40.
- Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. *Am Rev Respir Dis* 1986;133:1072-5.
- Satoh T. Recent advances in hepatotoxicity studies. *Korean J Toxicol* 1991;7:113-28.

Singh A, Bhat TK, Sharma OP. Clinical biochemistry of hepatotoxicity. *J Clin Toxicol* 2011;S4:001.
<http://dx.doi.org/10.4172/2161-0495.S4-001>

Sippel H, Stauffert I, Estler CJ. Protective effect of various calcium antagonists against experimentally induced calcium overload in isolated hepatocytes. *Biochem Pharmacol* 1993;1937-44.

Soon YY, Tan BKH. Evaluation of the hypoglycemic and antioxidant activities of *Morinda officinalis* in streptozocin-induced diabetic rats. *Singapore Med J* 2002;43:77–85.

Thapa BR, Walia A. Liver function tests and their interpretation. *Indian J Pediatr* 2007;74:663-71.

Thomas CE, Reed DJ. Current status of calcium in hepatocellular injury. *Hepatology* 1989;10:375-84.

Tikoo K, Tamta A, Ali IY, Gupta J, Gaikwad AB. Tannic acid prevents azidothymidine (AZT) induced hepatotoxicity and genotoxicity along with change in expression of PARG and histone H3 acetylation. *Toxicol Lett* 2008;177:90-6.

Tostmann A, Boeree MJ, Aarnoutse RE, de Lange Wiel CM, van der Ven Andre JAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. *J Gastroenterol Hepatol* 2008;23:192-202.

Vogel HG, Vogel WH. Potentiation of hexobarbital sleeping time. In: Vogel HG, Vogel WH: *Drug discovery and evaluation* (pp 267-8). Berlin: Springer-Verlag, 1997.

Wang N, Li P, Wang Y, Peng W, Wu Z, Tan S et al. Hepatoprotective effect of *Hypericum japonicum* extract and its fractions. *J Ethnopharmacol* 2008;116:1-6.

Westphal JF, Vetter D, Brogard JM. Hepatic side-effects of antibiotics. *J Antimicrob Chemother* 1994;33:387-401.

Zimmerman HJ, Maddrey WC. Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER (eds). *Diseases of the liver* (pp 707-83). Philadelphia, PA: Lippincott, 1993.